Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA's inaugural biosimilar review bumpier than first appeared

This article was originally published in SRA

Executive Summary

Sue Sutter explains how the US Food and Drug Administration's handling of issues around protein content differences, statistical analyses of quality data and immunogenicity testing for Sandoz's Zarxio may prove instructive for future 351(k) applicants.

Advertisement

Related Content

Biosimilar Advisory Committee Features Actual Debate About Biosimilarity
Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis
Advertisement
UsernamePublicRestriction

Register

PS118268

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel